Navigation Links
New Treatment Eyed for Hepatitis C
Date:1/20/2010

Class of compounds identified that inhibits viral growth in lab tests

WEDNESDAY, Jan. 20 (HealthDay News) -- A new class of compounds is able to inhibit replication of the hepatitis C virus (HCV) in laboratory tests, say U.S. scientists.

If they prove effective in humans, these compounds may offer an important new treatment option for patients infected with HCV, according to the Stanford University School of Medicine researchers. Current treatments for hepatitis C are only partially effective and often toxic.

HCV "infects over 150 million people worldwide, many of whom don't even know they have it. Chronic hepatitis C infection is the No. 1 cause of liver cancer and liver transplantation in the United States," study senior author Dr. Jeffrey Glenn, associate professor of gastroenterology and hepatology and director of Stanford's Center for Hepatitis and Liver Tissue Engineering, said in a news release.

The new class of compounds disrupts HCV's replication cycle by interfering with a process that doesn't ordinarily occur in uninfected cells. This means that HCV replication can be stopped with little or no toxicity to human cells.

The study was published online Jan. 20 in the journal Science Translational Medicine.

It could take a year to 18 months of preclinical and animal testing before these new compounds can be tested in human clinical trials, Glenn said.

He and his colleagues have equity in a privately held company to which Stanford has licensed intellectual property relevant to the new compounds.

More information

The American Academy of Family Physicians has more about hepatitis C.



-- Robert Preidt



SOURCE: Stanford University, news release, Jan. 20, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. New treatment boosts muscle function in myasthenia gravis
3. Broad-based group of physicians calls for improvement in stroke treatment
4. Cranberry Could Juice Up Ovarian Cancer Treatment
5. Non-medicinal treatment touted for pre-schoolers with ADHD
6. Nonmedicinal treatment touted for preschoolers with ADHD
7. U of M study: Early treatment can reverse heart damage
8. Biologic treatment for rheumatoid arthritis and the risk of cancer
9. New Treatment Explored for Cluster Headaches
10. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
11. 4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote Recovery Happens! Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... 2017 , ... An increase in wetter weather in the Northern California area ... that; a humdinger of an allergy season. A relief from drought conditions is most ... grass and weed pollen. , “Our patients have been reporting the typical allergy ...
(Date:6/25/2017)... ... ... is Men’s Health Month and the focus is on prostate cancer. Second only ... and the third most common cause of cancer related death today; lung cancer remains in ... diagnosed with prostate cancer during his lifetime. Those at highest risk are men ...
(Date:6/24/2017)... ... June 24, 2017 , ... ... Located at 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and ... so that visits to the dentist fit into their patients’ busy lifestyles. Dental365 ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality Institute ... Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively coordinate ... Alerts and Dashboards provide near real-time data about patients admitted to and/or discharged ...
(Date:6/23/2017)... ... June 23, 2017 , ... Yesterday, ... proposed healthcare bill to repeal and replace the Affordable Care Act (ACA). Like ... make significant cuts to Medicaid, a public health insurance program for low-income children, ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... 2017  Novavax, Inc., (Nasdaq: NVAX ) today ... trials of its RSV F protein recombinant nanoparticle vaccine candidate ... been published in the journal Vaccine ... prior scientific conferences). The Company previously announced top line ... developing the RSV F Vaccine with the goal of protecting ...
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
Breaking Medicine Technology: